Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of CT-3505 capsules in ALK-positive non-small cell lung cancer
CTR20191702Phase 2Active
- Sponsor
- Shouyao Holdings
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ficonalkib in non-small cell lung cancer (NSCLC), sponsored by Shouyao Holdings. Started Apr 2020; status: active.
02
Drugs
ficonalkib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20191702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191702.